Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter

[1] Naccarelli GV(2009)Increasing prevalence of atrial fibrillation and flutter in the United States Am J Cardiol 104 1534-1539

[2] Varker H(1995)The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 476-484

[3] Lin J(2008)ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and the physician consortium for performance improvement (writing committee to develop clinical performance measures for atrial fibrillation) developed in collaboration with the Heart Rhythm Society J Am Coll Cardiol 51 865-884

[4] Schulman KL(1998)Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 946-952

[5] Krahn AD(2002)A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 359-364

[6] Manfreda J(2008)Changing trends of hospital utilization in patients after their first episode of atrial fibrillation Am J Cardiol 102 568-572

[7] Tate RB(2006)Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903-1912

[8] Mathewson FA(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151

[9] Cuddy TE(2009)Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 668-678

[10] Estes NA(2010)Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials J Clin Epidemiol 63 1053-1058

[1] Naccarelli GV(2009)Increasing prevalence of atrial fibrillation and flutter in the United States Am J Cardiol 104 1534-1539

[2] Varker H(1995)The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 476-484

[3] Lin J(2008)ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and the physician consortium for performance improvement (writing committee to develop clinical performance measures for atrial fibrillation) developed in collaboration with the Heart Rhythm Society J Am Coll Cardiol 51 865-884

[4] Schulman KL(1998)Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 946-952

[5] Krahn AD(2002)A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 359-364

[6] Manfreda J(2008)Changing trends of hospital utilization in patients after their first episode of atrial fibrillation Am J Cardiol 102 568-572

[7] Tate RB(2006)Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903-1912

[8] Mathewson FA(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151

[9] Cuddy TE(2009)Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 668-678

[10] Estes NA(2010)Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials J Clin Epidemiol 63 1053-1058